SG11201903483VA - Compositions and methods for treating ezh2-mediated cancer - Google Patents
Compositions and methods for treating ezh2-mediated cancerInfo
- Publication number
- SG11201903483VA SG11201903483VA SG11201903483VA SG11201903483VA SG11201903483VA SG 11201903483V A SG11201903483V A SG 11201903483VA SG 11201903483V A SG11201903483V A SG 11201903483VA SG 11201903483V A SG11201903483V A SG 11201903483VA SG 11201903483V A SG11201903483V A SG 11201903483VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- gustave
- medicine
- new york
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111 0 DOI HIM 011101 0 011111a 0111101111101111101111 OEN Organization 0 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/081530 Al 03 May 2018 (03.05.2018) WIP0 I PCT (51) International Patent Classification: C07D 401/12 (2006.01) C07D 405/14 (2006.01) Published: C07D 409/14 (2006.01) — with international search report (Art. 21(3)) (21) International Application Number: PCT/US2017/058718 (22) International Filing Date: 27 October 2017 (27.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/414,195 28 October 2016 (28.10.2016) US (71) Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI [US/US]; One Gustave L. Levy Place, Box 1030, New York, New York 10029 (US). (72) Inventors: JIN, Jian; c/o Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, New _ York 10029 (US). PARSONS, Ramon; c/o Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New — York, NY 10029 (US). STRATIKOPOULOS, Ilias; c/o = Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029 (US). YANG, Xiaobao; c/o Icahn School of Medicine at Mount Sinai, One Gustave =_ = L. Levy Place, New York, NY 10029 (US). Agent: WONG, Albert et al.; Fish & Richardson P.C., P.O. = (74) Box 1022, Minneapolis, Minnesota 55440-1022 (US). = Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (81) _ = = — = = = = Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (84) = — = — 1-1 0 M in Il GC 0 --.... 00 1-1 (54) Title: COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER © ei (57) : Methods for designing bivalent compounds which selectively degrade/disrupt EZH2 and compositions and methods of 0 using such degraders/disruptors to treat EZH2-mediated cancer are provided.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662414195P | 2016-10-28 | 2016-10-28 | |
PCT/US2017/058718 WO2018081530A1 (en) | 2016-10-28 | 2017-10-27 | Compositions and methods for treating ezh2-mediated cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201903483VA true SG11201903483VA (en) | 2019-05-30 |
Family
ID=62024052
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201903483VA SG11201903483VA (en) | 2016-10-28 | 2017-10-27 | Compositions and methods for treating ezh2-mediated cancer |
SG10202104386UA SG10202104386UA (en) | 2016-10-28 | 2017-10-27 | Compositions and methods for treating ezh2-mediated cancer |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202104386UA SG10202104386UA (en) | 2016-10-28 | 2017-10-27 | Compositions and methods for treating ezh2-mediated cancer |
Country Status (12)
Country | Link |
---|---|
US (3) | US20190255041A1 (en) |
EP (1) | EP3532464A4 (en) |
JP (1) | JP2019537585A (en) |
KR (1) | KR20190084063A (en) |
CN (1) | CN110167924A (en) |
AU (2) | AU2017348322B8 (en) |
CA (1) | CA3041840A1 (en) |
EA (1) | EA201991071A1 (en) |
IL (1) | IL266053A (en) |
MX (1) | MX2019004950A (en) |
SG (2) | SG11201903483VA (en) |
WO (1) | WO2018081530A1 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180046208A (en) * | 2016-10-27 | 2018-05-08 | 삼성전자주식회사 | Method and Apparatus for Executing Application based on Voice Command |
EA201991071A1 (en) | 2016-10-28 | 2019-11-29 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | |
CA3045037A1 (en) | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cdk4/6-mediated cancer |
US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
EP3762381A4 (en) | 2018-03-06 | 2022-01-05 | Icahn School of Medicine at Mount Sinai | Serine threonine kinase (akt) degradation / disruption compounds and methods of use |
SI3784663T1 (en) | 2018-04-23 | 2023-11-30 | Celgene Corporation | Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma |
CN112457365B (en) * | 2019-09-09 | 2023-06-09 | 中国医学科学院药物研究所 | Functional molecules targeting proteolytic pathway, preparation and application thereof |
CN110862434B (en) * | 2019-10-28 | 2021-07-06 | 中山大学 | Compound capable of promoting TGF-beta 1 protein targeted degradation and preparation method and application thereof |
EP4053122A4 (en) * | 2019-10-31 | 2023-01-18 | Daegu-Gyeongbuk Medical Innovation Foundation | Compound comprising ezh2 inhibitor and e3 ligase binder and pharmaceutical composition for preventing or treating ezh2-associated disease comprising same as active ingredient |
CN111303133A (en) * | 2020-03-25 | 2020-06-19 | 清华大学 | Small molecule compound for degrading EZH2 protein |
CN112920176B (en) * | 2020-05-25 | 2022-11-04 | 四川大学华西医院 | Bifunctional compound capable of inducing PRC2 protein complex core subunit degradation, pharmaceutical composition and application |
PE20230732A1 (en) * | 2020-08-13 | 2023-05-03 | Hanmi Pharmaceutical Co Ltd | NOVEL DIOXOLISOQUINOLINONE DERIVATIVES AND USE THEREOF |
CN113214203A (en) * | 2020-12-16 | 2021-08-06 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | Small molecule compound based on EZH2 protein degradation and application thereof |
WO2022159650A1 (en) * | 2021-01-22 | 2022-07-28 | Icahn School Of Medicine At Mount Sinai | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF eEF1A2 |
US20230346953A1 (en) * | 2021-04-30 | 2023-11-02 | Northwestern University | Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (ezh2) and proteolysis-targeting chimeric derivatives thereof (protacs) that induce degradation of ezh2 |
WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5691147A (en) | 1994-06-02 | 1997-11-25 | Mitotix, Inc. | CDK4 binding assay |
US6486214B1 (en) | 1997-09-10 | 2002-11-26 | Rutgers, The State University Of New Jersey | Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby |
WO2001060814A2 (en) | 2000-02-15 | 2001-08-23 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
SI2076260T1 (en) | 2006-09-15 | 2011-05-31 | Celgene Corp | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same |
WO2008109104A1 (en) | 2007-03-07 | 2008-09-12 | The Regents Of The University Of California | Bivalent inhibitors of akt protein kinase |
EP2173723B3 (en) | 2007-07-05 | 2014-11-19 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
US20110172107A1 (en) | 2008-04-30 | 2011-07-14 | Fox Chase Cancer Center | Assay for identifying agents that modulate epigenetic silencing, and agents identified thereby |
CA2773131C (en) | 2009-09-04 | 2015-07-14 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
RS59275B1 (en) | 2010-02-11 | 2019-10-31 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
WO2012078492A1 (en) | 2010-12-06 | 2012-06-14 | Celgene Corporation | A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma |
KR102204989B1 (en) | 2012-01-12 | 2021-01-20 | 예일 유니버시티 | Compounds and Methods for the Enhanced Degradation of Targeted Proteins and Other Polypeptides by an E3 Ubiquitin Ligase |
EP2846784A4 (en) | 2012-05-11 | 2016-03-09 | Univ Yale | Compounds useful for promoting protein degradation and methods using same |
USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
SI2935222T1 (en) | 2012-12-21 | 2019-02-28 | Epizyme Inc. | Prmt5 inhibitors and uses thereof |
ES2687477T3 (en) | 2013-12-31 | 2018-10-25 | Xuanzhu Pharma Co., Ltd. | Kinase inhibitor and its use |
WO2015104677A1 (en) * | 2014-01-10 | 2015-07-16 | Piramal Enterprises Limited | Heterocyclic compounds as ezh2 inhibitors |
CN106458993A (en) * | 2014-04-14 | 2017-02-22 | 阿尔维纳斯股份有限公司 | Imide-based modulators of proteolysis and associated methods of use |
PT3154594T (en) | 2014-06-13 | 2023-08-17 | Bach Biosciences Llc | Fap-activated therapeutic agents, and uses related thereto |
EP3214935A4 (en) * | 2014-11-06 | 2018-08-29 | Dana-Farber Cancer Institute, Inc. | Ezh2 inhibitors and uses thereof |
US10479997B2 (en) | 2014-12-01 | 2019-11-19 | Novartis Ag | Compositions and methods for diagnosis and treatment of prostate cancer |
JP6815318B2 (en) * | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | How to Induce Targeted Proteolysis by Bifunctional Molecules |
WO2016106518A1 (en) * | 2014-12-29 | 2016-07-07 | 深圳市日上光电股份有限公司 | Conducting line integrated illumination lamp box |
AR103297A1 (en) | 2014-12-30 | 2017-05-03 | Forma Therapeutics Inc | PIRROLO AND PIRAZOLOPIRIMIDINAS AS INHIBITORS OF THE SPECIFIC PROTEASE 7 OF UBIQUITINA |
US20180000906A1 (en) | 2015-01-16 | 2018-01-04 | Vedantra Pharmaceuticals, Inc. | Multilamellar lipid vesicle compositions including a conjugated anaplastic lymphoma kinase (alk) variant and uses thereof |
KR20230175343A (en) * | 2015-03-18 | 2023-12-29 | 아비나스 오퍼레이션스, 인코포레이티드 | Compounds and methods for the enhanced degradation of targeted proteins |
US10988737B2 (en) | 2015-04-28 | 2021-04-27 | Universite De Strasbourg | Clinical gene signature-based human cell culture model and uses thereof |
EP3312182B9 (en) | 2015-06-22 | 2022-06-29 | Ono Pharmaceutical Co., Ltd. | Brk inhibitory compound |
CN105085620B (en) | 2015-06-25 | 2018-05-08 | 中山大学附属第一医院 | A kind of compound for targeting ubiquitination degraded Smad3 |
WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
CN108137507A (en) * | 2015-07-10 | 2018-06-08 | 阿尔维纳斯股份有限公司 | Proteolysis conditioning agent and relevant application method based on MDM2 |
RU2018105094A (en) * | 2015-07-13 | 2019-08-14 | Арвинас, Инк. | ALANINE-BASED PROTEOLYSIS MODULATORS AND RELATED APPLICATION METHODS |
US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
WO2017040990A1 (en) | 2015-09-03 | 2017-03-09 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
MX2018005340A (en) * | 2015-11-02 | 2018-05-17 | Univ Yale | Proteolysis targeting chimera compounds and methods of preparing and using same. |
EP3423451B1 (en) | 2016-03-01 | 2022-08-17 | Propellon Therapeutics Inc. | Inhibitors of wdr5 protein-protein binding |
WO2017147701A1 (en) | 2016-03-01 | 2017-09-08 | Ontario Institute For Cancer Research (Oicr) | Inhibitors of wdr5 protein-protein binding |
CA3018434A1 (en) * | 2016-04-22 | 2017-10-26 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use |
EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
CN109562107A (en) | 2016-05-10 | 2019-04-02 | C4医药公司 | Heterocycle degron body for target protein degradation |
AR109595A1 (en) | 2016-09-09 | 2018-12-26 | Incyte Corp | PIRAZOLOPIRIMIDINE COMPOUNDS AND USES OF THESE AS HPK1 INHIBITORS |
US10160763B2 (en) | 2016-09-13 | 2018-12-25 | Vanderbilt University | WDR5 inhibitors and modulators |
EA201991071A1 (en) | 2016-10-28 | 2019-11-29 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | |
CA3045037A1 (en) | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cdk4/6-mediated cancer |
ES2909234T3 (en) | 2016-12-21 | 2022-05-05 | Ono Pharmaceutical Co | 6-amino-7,9-dihydro-8H-purin-8-one compounds as Brk inhibitors |
US20210283261A1 (en) | 2017-12-05 | 2021-09-16 | Icahn School Of Medicine At Mount Sinai | Compositions and Methods for Treating ALK-Mediated Cancer |
CA3091041A1 (en) | 2018-02-22 | 2019-08-29 | Ichan School Of Medicine At Mount Sinai | Protein arginine methyltransferase 5 (prmt5) degradation / disruption compounds and methods of use |
EP3762381A4 (en) | 2018-03-06 | 2022-01-05 | Icahn School of Medicine at Mount Sinai | Serine threonine kinase (akt) degradation / disruption compounds and methods of use |
AU2019271208A1 (en) | 2018-05-15 | 2020-12-03 | Northwestern University | Formulations and methods for the prevention and treatment of tumor metastasis and tumorigenesis |
US20220348580A1 (en) | 2018-06-21 | 2022-11-03 | Icahn School Of Medicine At Mount Sinai | Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use |
CN114269749A (en) | 2019-06-10 | 2022-04-01 | 苏特罗生物制药公司 | 5H-pyrrolo [3,2-d ] pyrimidine-2, 4-diamino compounds and antibody conjugates thereof |
US20220274980A1 (en) | 2019-07-30 | 2022-09-01 | The Scripps Research Institute | Pharmacological inhibitors of the enl yeats domain |
US20210395244A1 (en) | 2020-06-01 | 2021-12-23 | Icahn School Of Medicine At Mount Sinai | Mitogen-activated protein kinase kinase (mek) degradation compounds and methods of use |
CN112778303A (en) | 2020-12-31 | 2021-05-11 | 武汉九州钰民医药科技有限公司 | Preparation method of CDK4/6 kinase inhibitor SHR6390 |
-
2017
- 2017-10-27 EA EA201991071A patent/EA201991071A1/en unknown
- 2017-10-27 EP EP17863645.2A patent/EP3532464A4/en active Pending
- 2017-10-27 US US16/345,591 patent/US20190255041A1/en not_active Abandoned
- 2017-10-27 KR KR1020197015152A patent/KR20190084063A/en not_active Application Discontinuation
- 2017-10-27 JP JP2019522841A patent/JP2019537585A/en active Pending
- 2017-10-27 CN CN201780081246.8A patent/CN110167924A/en active Pending
- 2017-10-27 AU AU2017348322A patent/AU2017348322B8/en active Active
- 2017-10-27 MX MX2019004950A patent/MX2019004950A/en unknown
- 2017-10-27 CA CA3041840A patent/CA3041840A1/en not_active Abandoned
- 2017-10-27 SG SG11201903483VA patent/SG11201903483VA/en unknown
- 2017-10-27 SG SG10202104386UA patent/SG10202104386UA/en unknown
- 2017-10-27 WO PCT/US2017/058718 patent/WO2018081530A1/en unknown
-
2019
- 2019-04-15 IL IL266053A patent/IL266053A/en unknown
-
2020
- 2020-07-10 US US16/926,418 patent/US11510920B2/en active Active
-
2022
- 2022-03-03 AU AU2022201488A patent/AU2022201488A1/en active Pending
- 2022-11-01 US US17/978,696 patent/US20230114294A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20190255041A1 (en) | 2019-08-22 |
MX2019004950A (en) | 2019-09-26 |
CA3041840A1 (en) | 2018-05-03 |
EA201991071A1 (en) | 2019-11-29 |
US11510920B2 (en) | 2022-11-29 |
US20200338070A1 (en) | 2020-10-29 |
KR20190084063A (en) | 2019-07-15 |
EP3532464A4 (en) | 2020-07-08 |
WO2018081530A1 (en) | 2018-05-03 |
AU2017348322B2 (en) | 2021-12-09 |
AU2017348322A8 (en) | 2021-12-23 |
CN110167924A (en) | 2019-08-23 |
EP3532464A1 (en) | 2019-09-04 |
AU2017348322B8 (en) | 2021-12-23 |
SG10202104386UA (en) | 2021-05-28 |
JP2019537585A (en) | 2019-12-26 |
US20230114294A1 (en) | 2023-04-13 |
AU2017348322A1 (en) | 2019-06-13 |
IL266053A (en) | 2019-06-30 |
AU2022201488A1 (en) | 2022-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201903483VA (en) | Compositions and methods for treating ezh2-mediated cancer | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
SG11201900480YA (en) | Anti-tim-3 antibodies | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201811225RA (en) | Ar+ breast cancer treatment methods | |
SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
SG11201808306PA (en) | Treatment of cancer with tg02 | |
SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201811416VA (en) | Crystalline solid forms of a bet inhibitor | |
SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
SG11201903770UA (en) | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders | |
SG11201810333UA (en) | Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders | |
SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
SG11201810078PA (en) | Stabilized pre-fusion rsv f proteins | |
SG11201809237RA (en) | Oxaborole esters and uses thereof | |
SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors | |
SG11201900043TA (en) | Antibody formulations |